Ezutromid

Drug Profile

Ezutromid

Alternative Names: BMN-195; SMT-1100; SMTC-1100; VOX-C1100

Latest Information Update: 17 May 2017

Price : $50

At a glance

  • Originator VASTox
  • Developer Summit Therapeutics
  • Class Benzoxazoles; Naphthalenes; Small molecules; Sulfoxides
  • Mechanism of Action Utrophin activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Duchenne muscular dystrophy

Most Recent Events

  • 15 May 2017 Summit Therapeutics completes enrolment in the phase II PhaseOut DMD trial for Duchenne muscular dystrophy in United Kingdom and USA
  • 29 Mar 2017 Summit Therapeutics submits regulatory applications to the UK Medicines and Healthcare products Regulatory Agency and the US Food and Drug Administration for approval to extend the phase II PhaseOut DMD trial into an open-label extension phase
  • 27 Mar 2017 Summit Therapeutics plans long term extension phase of the phase II PhaseOut DMD trial in Duchenne muscular dystrophy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top